Stratified Medicine to Optimise Treatment for Hepatitis C Virus Infection
Lead Research Organisation:
University of Oxford
Department Name: Experimental Medicine
Abstract
Stratified Medicine is a type of personalised medicine where treatments are directed specifically at people who are most likely to respond to them, often using detailed information about individuals. We believe that the treatment of patients with hepatitis C virus (HCV) would benefit enormously from this approach.
About 300,000 people in the UK are infected with HCV, only half of whom have been diagnosed as carrying the virus. The virus has a high tendency to persist as the body's immune system is usually unable to clear infection. HCV infects the liver, causing liver cirrhosis (scarring), liver failure and liver cancer. HCV exists in different genetic forms called genotypes. In the UK, most infections are caused by either genotype 1 or 3, which occur at about equal frequency.
Treatment for HCV has consisted of two drugs interferon and ribavirin. Approximately half of patients receiving treatment respond and are successfully cured of infection. Until recently, no additional drugs were available to treat those who failed treatment. The number of people who develop severe liver disease from HCV is expected to continue to rise over the next two decades. Those who develop liver failure can be given a transplant but the transplanted organ is rapidly infected with the virus and often becomes diseased within a few years.
New drugs, which directly act against the virus (called DAAs), are being used in combination with interferon and ribavirin in NHS patients for the first time in the clinic in 2012. DAA drugs increase the cure rate to 70%. However, there are drawbacks: the drugs are very expensive costing in excess of £20,000 per patient; the virus can become resistant to new drugs, rendering them useless and increasing the frequency of resistant strains in the community; the first wave of new drugs are effective against genotype 1 but not genotype 3 strains; additional side effects can be associated with the new drugs, so that treatment may be stopped before the virus is eliminated.
We have developed a team of experts in the clinical care of HCV patients, who will work with HCV scientists, in partnership with industry. Combining expertise in this way should serve to benefit patients. The group is already working well together collecting blood samples and information from 10,000 people across the UK into a single bio-bank, supported by government infrastructure. We aim to assess the genetic make up of both the virus and the infected person. We will also look at the way in which the immune system responds to the virus, and measure protein markers in the blood. We will assess these in patients receiving therapy and also in those with serious liver disease to try to work out in advance who will develop further complications of their disease. A unique feature of our group will be the ability to draw all these strands together.
We will develop new technologies so that we rapidly obtain the host and viral sequence in thousands of infected people. In this way we hope to improve treatment options for patients so that the right therapies are given to patients who are most likely to benefit from them. We will focus our efforts especially on HCV genotype 3, which is a particular problem in UK patients, and also on patients with more serious liver disease, who are more difficult to treat with the new therapies. Ultimately we hope to predict the likelihood of treatment response in individuals, and possibly through our investigations develop new therapies. This could bring considerable cost-savings to the NHS and means that drugs are given to HCV-infected people who are most likely to respond to them.
About 300,000 people in the UK are infected with HCV, only half of whom have been diagnosed as carrying the virus. The virus has a high tendency to persist as the body's immune system is usually unable to clear infection. HCV infects the liver, causing liver cirrhosis (scarring), liver failure and liver cancer. HCV exists in different genetic forms called genotypes. In the UK, most infections are caused by either genotype 1 or 3, which occur at about equal frequency.
Treatment for HCV has consisted of two drugs interferon and ribavirin. Approximately half of patients receiving treatment respond and are successfully cured of infection. Until recently, no additional drugs were available to treat those who failed treatment. The number of people who develop severe liver disease from HCV is expected to continue to rise over the next two decades. Those who develop liver failure can be given a transplant but the transplanted organ is rapidly infected with the virus and often becomes diseased within a few years.
New drugs, which directly act against the virus (called DAAs), are being used in combination with interferon and ribavirin in NHS patients for the first time in the clinic in 2012. DAA drugs increase the cure rate to 70%. However, there are drawbacks: the drugs are very expensive costing in excess of £20,000 per patient; the virus can become resistant to new drugs, rendering them useless and increasing the frequency of resistant strains in the community; the first wave of new drugs are effective against genotype 1 but not genotype 3 strains; additional side effects can be associated with the new drugs, so that treatment may be stopped before the virus is eliminated.
We have developed a team of experts in the clinical care of HCV patients, who will work with HCV scientists, in partnership with industry. Combining expertise in this way should serve to benefit patients. The group is already working well together collecting blood samples and information from 10,000 people across the UK into a single bio-bank, supported by government infrastructure. We aim to assess the genetic make up of both the virus and the infected person. We will also look at the way in which the immune system responds to the virus, and measure protein markers in the blood. We will assess these in patients receiving therapy and also in those with serious liver disease to try to work out in advance who will develop further complications of their disease. A unique feature of our group will be the ability to draw all these strands together.
We will develop new technologies so that we rapidly obtain the host and viral sequence in thousands of infected people. In this way we hope to improve treatment options for patients so that the right therapies are given to patients who are most likely to benefit from them. We will focus our efforts especially on HCV genotype 3, which is a particular problem in UK patients, and also on patients with more serious liver disease, who are more difficult to treat with the new therapies. Ultimately we hope to predict the likelihood of treatment response in individuals, and possibly through our investigations develop new therapies. This could bring considerable cost-savings to the NHS and means that drugs are given to HCV-infected people who are most likely to respond to them.
Technical Summary
HCV infects 300,000 people within the UK and is an MRC priority research area. We have developed a flexible and dynamic UK wide consortium(STOP-HCV) that will use patient stratification to optimise treatment of infected patients. The consortium builds on existing cutting edge clinical and scientific expertise, in genuine partnership with industry, supported by NIHR infrastructure.
Our overarching aim is to define and develop a deeper understanding of patient strata and to develop prognostic models so that rational treatment strategies can be deployed. In a new era of novel Directly Acting Antiviral (DAA) therapies, treating only a subset of patients with DAA will cost the NHS an estimated £96 million/year with an expected overall treatment failure rate of 30%. Moreover, 40% of patients receiving DAAs would respond to current cheaper therapies. Therefore, refined patient stratification will be of enormous clinical and economic benefit. A focus of our program will be study of HCV genotype-3 infection, highly prevalent in the UK, with a characteristic clinical phenotype, and a high relapse rate with standard therapy. We will also focus on difficult-to-treat patient groups such as those with cirrhosis and those co-infected with HIV, where optimal management pathways will be of particular benefit in patients.
Our consortium is underpinned by HCV Research UK, a network of 18 UK centres biobanking samples from 10,000 HCV infected patients, linked to a state-of-the-art clinical database. The consortium has been purposefully constructed to support rational enquiry and will be divided into integrated themes including cohort development, host and viral genomics, immune phenotyping and biomarker evaluation. The program is supported by health economic, methodological, statistical, and bioinformatics expertise. The STOP-HCV consortium draws together UK expertise in collaborative working to ensure stratification at a national level for the optimal treatment of patients with HCV
Our overarching aim is to define and develop a deeper understanding of patient strata and to develop prognostic models so that rational treatment strategies can be deployed. In a new era of novel Directly Acting Antiviral (DAA) therapies, treating only a subset of patients with DAA will cost the NHS an estimated £96 million/year with an expected overall treatment failure rate of 30%. Moreover, 40% of patients receiving DAAs would respond to current cheaper therapies. Therefore, refined patient stratification will be of enormous clinical and economic benefit. A focus of our program will be study of HCV genotype-3 infection, highly prevalent in the UK, with a characteristic clinical phenotype, and a high relapse rate with standard therapy. We will also focus on difficult-to-treat patient groups such as those with cirrhosis and those co-infected with HIV, where optimal management pathways will be of particular benefit in patients.
Our consortium is underpinned by HCV Research UK, a network of 18 UK centres biobanking samples from 10,000 HCV infected patients, linked to a state-of-the-art clinical database. The consortium has been purposefully constructed to support rational enquiry and will be divided into integrated themes including cohort development, host and viral genomics, immune phenotyping and biomarker evaluation. The program is supported by health economic, methodological, statistical, and bioinformatics expertise. The STOP-HCV consortium draws together UK expertise in collaborative working to ensure stratification at a national level for the optimal treatment of patients with HCV
Planned Impact
The economic and societal impacts of our consortium will be far reaching:
Enhancing the quality of life, health and well- being: Our overarching aim is to use stratification to enhance clinical decision-making and thereby achieve maximum effectiveness and cost-effectiveness of therapeutic regimens for hepatitis C virus (HCV) infection. We also aim to understand disease mechanisms that define patient strata so that new rational therapeutic approaches can be developed and deployed. We will focus on patients that are difficult to treat with advanced disease, and those with genotype-3 infection a strain that is particularly common in the UK. To achieve this we have developed a consortium in partnership with industry that unites academics from different disciplines, and clinicians at the forefront of the field. Impact on society will be achieved through direct health benefits to the 300,000 patients infected with HCV within the UK, many of whom develop liver cirrhosis, liver failure and hepatocellular cancer.
Contributing towards evidence based policy-making: Through integration between scientists, clinicians, statisticians and health economics, our consortium will drive national guidelines for the treatment of HCV.
Economic impacts: New directly acting antivirals (DAAs) are now available at a cost of >£20,000/treatment course. Treating only 1% of infected people will cost the NHS £96 million. With effective stratification these therapies will be given to those people most likely to obtain maximum benefit with direct economic savings to the NHS.
Economic prosperity:
Our program of work involves the identification and integrated analysis of host and viral genomic markers and other biomarkers of disease progression and treatment response. This work may enhance UK competitiveness and prosperity (i) through the commercialisation and exploitation of predictive models of clinical outcomes, (ii) the development of high throughput assays for in-vitro assays of drug resistance testing, and (iii) high throughput integrative genomics. (vi) innovative statistical methodology that may be commercially exploited.
Furthermore, New insights into disease biology may lead to the development of novel therapeutic avenues and early phase clinical studies.
Our work will increase innovative research capacity within academic organisations that seek to develop new therapies and diagnostic tools.
Industry: Our consortium has been developed in alignment with industry needs in the arenas of both HCV pharama and diagnostics, and the industrial sector will benefit directly from our consortium.
Voluntary sector: The hepatitis C Trust, a charity run by patients for patients is represented on the STOP-HCV steering committee. One additional direct spin-off from the consortium will be an increased participation of UK patients in clinical trials - an area in which historically, the UK has performed very badly.
Technological advances: Society will also benefit through technological advances made within the strategic aims of the projects. This will include the deployment and high throughput of novel genetic sequencing technologies and integrative platforms for host and viral genomics, immune phenotyping, and biomarkers.
Realistic time scales for benefits to be achieved is 5 years.
Enhancing the quality of life, health and well- being: Our overarching aim is to use stratification to enhance clinical decision-making and thereby achieve maximum effectiveness and cost-effectiveness of therapeutic regimens for hepatitis C virus (HCV) infection. We also aim to understand disease mechanisms that define patient strata so that new rational therapeutic approaches can be developed and deployed. We will focus on patients that are difficult to treat with advanced disease, and those with genotype-3 infection a strain that is particularly common in the UK. To achieve this we have developed a consortium in partnership with industry that unites academics from different disciplines, and clinicians at the forefront of the field. Impact on society will be achieved through direct health benefits to the 300,000 patients infected with HCV within the UK, many of whom develop liver cirrhosis, liver failure and hepatocellular cancer.
Contributing towards evidence based policy-making: Through integration between scientists, clinicians, statisticians and health economics, our consortium will drive national guidelines for the treatment of HCV.
Economic impacts: New directly acting antivirals (DAAs) are now available at a cost of >£20,000/treatment course. Treating only 1% of infected people will cost the NHS £96 million. With effective stratification these therapies will be given to those people most likely to obtain maximum benefit with direct economic savings to the NHS.
Economic prosperity:
Our program of work involves the identification and integrated analysis of host and viral genomic markers and other biomarkers of disease progression and treatment response. This work may enhance UK competitiveness and prosperity (i) through the commercialisation and exploitation of predictive models of clinical outcomes, (ii) the development of high throughput assays for in-vitro assays of drug resistance testing, and (iii) high throughput integrative genomics. (vi) innovative statistical methodology that may be commercially exploited.
Furthermore, New insights into disease biology may lead to the development of novel therapeutic avenues and early phase clinical studies.
Our work will increase innovative research capacity within academic organisations that seek to develop new therapies and diagnostic tools.
Industry: Our consortium has been developed in alignment with industry needs in the arenas of both HCV pharama and diagnostics, and the industrial sector will benefit directly from our consortium.
Voluntary sector: The hepatitis C Trust, a charity run by patients for patients is represented on the STOP-HCV steering committee. One additional direct spin-off from the consortium will be an increased participation of UK patients in clinical trials - an area in which historically, the UK has performed very badly.
Technological advances: Society will also benefit through technological advances made within the strategic aims of the projects. This will include the deployment and high throughput of novel genetic sequencing technologies and integrative platforms for host and viral genomics, immune phenotyping, and biomarkers.
Realistic time scales for benefits to be achieved is 5 years.
Organisations
- University of Oxford (Lead Research Organisation)
- GLASGOW CALEDONIAN UNIVERSITY (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- University of Bristol (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- PUBLIC HEALTH ENGLAND (Collaboration)
- Oncimmune (Collaboration)
- Janssen Diagnostics (Collaboration)
- Hepatitis C Trust (Collaboration)
- Gilead Sciences, Inc. (Collaboration)
- University of Dundee (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- MERCK (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- London School of Hygiene and Tropical Medicine (LSHTM) (Collaboration)
- MSD (United States) (Project Partner)
- Medivir U K Ltd (Project Partner)
- Conatus Pharmaceuticals (United States) (Project Partner)
- Oncimmune Ltd (Project Partner)
- Okairos (Project Partner)
- United Therapeutics (United Kingdom) (Project Partner)
- Gilead Sciences Limited (Project Partner)
Publications
Afik S
(2017)
Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state.
in Nucleic acids research
Ansari M
(2021)
In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control
in Wellcome Open Research
Ansari MA
(2019)
Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.
in eLife
Ansari MA
(2017)
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.
in Nature genetics
Azim Ansari M
(2016)
Genome-To-Genome Virus-Host Analysis Reveals HCV Genotype 3 Viral Polymorphisms Linked Viral Load and to Host HLA Class-I/II and IL28B Alleles
in Journal of Hepatology
Bonsall D
(2015)
ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens
in F1000Research
Bonsall D
(2016)
Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.
in Emerging infectious diseases
Bonsall D
(2018)
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.
in Infection and drug resistance
Bradshaw D
(2022)
Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing.
in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Bradshaw D
(2019)
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group.
in The Journal of infection
Cardo L
(2018)
Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in cellulo.
in Scientific reports
Cheung MCM
(2016)
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
in Journal of hepatology
Cooke G
(2021)
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C
in Wellcome Open Research
Cooke GS
(2021)
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C.
in Wellcome open research
Da Silva Filipe A
(2017)
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.
in Journal of hepatology
Fan R
(2020)
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
in Journal of hepatology
Farquhar MJ
(2017)
Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
in Journal of hepatology
Fawsitt CG
(2020)
Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus.
in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Fawsitt CG
(2019)
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Fletcher NF
(2017)
TNF superfamily members promote hepatitis C virus entry via an NF-?B and myosin light chain kinase dependent pathway.
in The Journal of general virology
Foster GR
(2016)
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
in Journal of hepatology
Gangadharan B
(2015)
PTH-092 Discovery and quantitation of novel liver fibrosis biomarkers using proteomics
in Gut
Gonçalves-Carneiro D
(2017)
The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis.
in Journal of virology
Grove J
(2017)
A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.
in Wellcome open research
Guha IN
(2019)
Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation.
in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Hamill V
(2023)
Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK
in Liver International
Hedegaard DL
(2017)
High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.
in Journal of hepatology
Hill A
(2014)
Medicine. Hepatitis C can be cured globally, but at what cost?
in Science (New York, N.Y.)
Iles JC
(2015)
Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing.
in Journal of clinical microbiology
Innes H
(2021)
Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection
in JHEP reports : innovation in hepatology
Innes H
(2022)
Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis
in Clinical and Translational Gastroenterology
Innes H
(2021)
The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization.
in Gastroenterology
Innes H
(2022)
The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis.
in Hepatology communications
Innes H
(2020)
Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1.
in Gastroenterology
Innes H
(2021)
Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection.
in JHEP reports : innovation in hepatology
Johnson PJ
(2021)
Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection.
in Journal of viral hepatitis
Ko C
(2018)
Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
in Journal of hepatology
Kumar A
(2016)
Multiple reaction monitoring and multiple reaction monitoring cubed based assays for the quantitation of apolipoprotein F.
in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Lai AG
(2018)
Glucose and glutamine availability regulate HepG2 transcriptional responses to low oxygen.
in Wellcome open research
Lee WJ
(2021)
The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation.
in Cellular and molecular gastroenterology and hepatology
| Description | Guidelines for HCV resistance testing (PHE HCV Resistance Group) |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | PHE HCV Resistance Group published guidance on the use of hepatitis C virus resistance testing in clinical practice. This working document aims to support clinicians treating people with HCV, where the issue of resistance may be a factor in clinical decision-making. |
| URL | https://www.gov.uk/government/publications/antiviral-resistance-testing-in-the-management-of-hepatit... |
| Description | Big Data for Human Health Seed Grant |
| Amount | $81,000 (USD) |
| Organisation | Li Ka Shing Foundation |
| Sector | Charity/Non Profit |
| Country | Hong Kong |
| Start | 04/2014 |
| End | 03/2015 |
| Description | Collaborative Award in Science |
| Amount | £3,350,722 (GBP) |
| Funding ID | 206296/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2022 |
| Description | DPhil studentship-NHIC STOP-HCV |
| Amount | £130,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 08/2018 |
| Description | Efficacy & Mechanism Evaluation (EME) programme |
| Amount | £1,700,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 02/2018 |
| Description | Investigator Sponsored Research |
| Amount | £91,500 (GBP) |
| Organisation | Gilead Sciences, Inc. |
| Sector | Private |
| Country | United States |
| Start | 03/2018 |
| End | 05/2019 |
| Description | Investigator award: Innate-like T cells and integration of host defence |
| Amount | £2,035,864 (GBP) |
| Funding ID | 222426/Z/21/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 01/2027 |
| Description | MRC Global Challenges Research Fund |
| Amount | £456,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2019 |
| Description | Nottingham BRU funds |
| Amount | £50,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2016 |
| Description | Oxford NIHR principle fellow award |
| Amount | £45,000 (GBP) |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 02/2018 |
| Description | Senior Investigator Award |
| Amount | £1,600,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 07/2022 |
| Description | The Early Detection of Hepatocellular Liver Cancer [DeLIVER]. Early Detection Committee - Programme Award |
| Amount | £257,267,645 (GBP) |
| Funding ID | C30358/A29725 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 02/2025 |
| Description | Wellcome Trust Institutional Strategic Support Fund |
| Amount | £62,000 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2018 |
| Title | Antibody-free detection and quantitation of serum protein biomarkers for liver fibrosis in hepatitis C patients |
| Description | We have developed a mass spectrometry based assay to detect and quantify serum protein biomarkers for liver fibrosis in hepatitis C patients. In this method, tryptic peptides and their fragments are analysed by mass spectrometry. https://www.ncbi.nlm.nih.gov/pubmed/27592286; https://www.ncbi.nlm.nih.gov/pubmed/28935895. We now plan to use this method to detect and quantify our biomarkers using serum samples from hepatitis C patients who have had a FibroScan. |
| Type Of Material | Biological samples |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | This is the first ever antibody-free serum protein biomarker assay for liver fibrosis. Also this is the only assay capable of quantifying several biomarkers using a single calibration curve with a universal calibration mix. Ulike other assays in the clinic, our assay can generate this calibration curve and determine the concentration of biomarkers in a single acquisition. |
| URL | https://www.sciencedirect.com/science/article/pii/S1570023216307036?via%3Dihub#sec0100 |
| Title | In vitro HCV replicon system |
| Description | The STOP-HCV consortium has successfully established a hepatitis C virus (HCV) replicon system to measure the replication/fitness of HCV in vitro. The replicon system provides a valuable tool for monitoring the susceptibility and resistance of a wide range of HCV genotypes to direct-acting antiviral drugs, and determining the relevance of viral SNPs identified in vivo. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | The system is currently being used to assess the impact, and relevance, of baseline HCV resistance associated substitutions on treatment outcome. The initial focus has been with the drugs sofosbuvir and daclatisvir, but studies are being extended to include the most recent generation of licensed HCV direct-acting antiviral drugs. |
| Title | NGS for HCV |
| Description | NGS for ful length HCV sequencing |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | The first tool for high throughput HCV sequencing |
| Title | Statistical methods for joint host and viral genome association analysis |
| Description | Statistical methods developed in order to perform joint host and pathogen genome wide association analysis |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | To be determined |
| Title | HCV-GLUE |
| Description | An online resource for the analysis of HCV sequence data. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | STOP-HCV is working closely with the team at the MRC-CVR in Glasgow to implement HCV-GLUE as a tool for the community (for both researchers and clinicians). |
| URL | http://hcv.glue.cvr.ac.uk/#home |
| Title | SNORK |
| Description | Snork is designed generate and report on on HCV whole-genome sequencing and drug resistance. |
| Type Of Material | Data handling & control |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | STOP-HCV Oxford is currently collaborating with Public Health England (PHE) to test the Snork pipeline in the hope that the ve-SEQ probe-based enrichment protocol and the Snork bioinformatics pipeline for interpreting the data will form the basis of routine Hepatitis C virus surveillance by PHE. |
| Title | STOP-HCV patient registry |
| Description | A database containing an anonymised, searchable listing of all patients whose samples have been analysed within STOP-HCV studies |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | This registry allows STOP-HCV researchers to easily identify and prioritise relevant sub-groups of patients for future analyses |
| URL | https://stop-hcv.nottingham.ac.uk |
| Description | Birmingham-STOP-HCV |
| Organisation | University of Birmingham |
| Department | School of Immunity and Infection |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | none to report to date |
| Start Year | 2013 |
| Description | Dundee-STOP-HCV |
| Organisation | University of Dundee |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | none to report to date |
| Start Year | 2013 |
| Description | Gilead Sciences - Boson study |
| Organisation | Gilead Sciences, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | Intellectual input into protocol, recruitment of UK patients, analysis of samples and data from patients enrolled into the study |
| Collaborator Contribution | Provision of samples and data from patients enrolled in the study |
| Impact | Clinical findings from the study were published in 2015 (Foster et al; Gastroenterology). The success of UK recruitment to this study resulted in an increased confidence by Pharma to undertake Phase 3 trials in hepatitis C within the UK. Two further studies have been initiated - Gilead ASTRAL-1 study, Merck C-ISLE study. Further publications describing joint host and viral genome association studies, from use of patient samples, have been listed elsewhere (Pedergnana et al) |
| Start Year | 2013 |
| Description | Glasgow - HCV NGS pilot |
| Organisation | University of Glasgow |
| Department | MRC - University of Glasgow Centre for Virus Research |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge and expertise |
| Collaborator Contribution | Provision of samples and data, sharing of knowledge and expertise |
| Impact | This collaboration formed part of the STOP-HCV pilot HCV next generation sequencing study - an exercise to formally compare HCV next generation sequencing methods undertaken in different UK centres. Results of the pilot study have been accepted for presentation at the 2016 EASL Liver meeting (April) and a manuscript is under review at the Journal of Clinical Microbiology. |
| Start Year | 2013 |
| Description | Glasgow Caledonian University |
| Organisation | Glasgow Caledonian University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Research funding, sharing knowledge and expertise |
| Collaborator Contribution | Investigation into the development of a prognostic model for HCV-associated cirrhosis |
| Impact | The collaboration is at its initial stages |
| Start Year | 2018 |
| Description | Health economics-STOP-HCV |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Department | Faculty of Public Health and Policy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | Publication describing how HCV treatment should be prioritised in the era of new direct acting antiviral drugs |
| Start Year | 2013 |
| Description | Health economics-STOP-HCV |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Department | Faculty of Public Health and Policy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | Publication describing how HCV treatment should be prioritised in the era of new direct acting antiviral drugs |
| Start Year | 2013 |
| Description | Health economics-STOP-HCV |
| Organisation | University of Bristol |
| Department | School of Social and Community Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | Publication describing how HCV treatment should be prioritised in the era of new direct acting antiviral drugs |
| Start Year | 2013 |
| Description | Health economics-STOP-HCV |
| Organisation | University of Bristol |
| Department | School of Social and Community Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | Publication describing how HCV treatment should be prioritised in the era of new direct acting antiviral drugs |
| Start Year | 2013 |
| Description | Hepatitis C Trust-STOP-HCV |
| Organisation | Hepatitis C Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Sharing of knowledge and expertise |
| Collaborator Contribution | Sharing of knowledge and expertise |
| Impact | Engagement with patient groups, patient perspective on clinical studies and policies related to STOP-HCV Consortium |
| Start Year | 2013 |
| Description | Imperial - STOP-HCV-1 |
| Organisation | Imperial College London |
| Department | Imperial College Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Sharing of knowledge & expertise, intellectual input into study protocol for STOP-HCV-1 trial |
| Collaborator Contribution | Sharing of knowledge & expertise, provision of samples and data from STOP-HCV-1 trial for analysis |
| Impact | Trial in progress, actively recruiting patients |
| Start Year | 2013 |
| Description | Imperial - STOP-HCV-1 |
| Organisation | University of Oxford |
| Department | Oxford Clinical Trials Unit (CTU) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise, intellectual input into study protocol for STOP-HCV-1 trial |
| Collaborator Contribution | Sharing of knowledge & expertise, provision of samples and data from STOP-HCV-1 trial for analysis |
| Impact | Trial in progress, actively recruiting patients |
| Start Year | 2013 |
| Description | Janssen-STOP-HCV |
| Organisation | Janssen Diagnostics |
| Country | United States |
| Sector | Private |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise, exploration of use of miRNA as a biomarker for liver disease progression |
| Impact | Preliminary studies to Identify miRNA profiles associated with different stages of liver fibrosis completed. |
| Start Year | 2013 |
| Description | Merck-STOP-HCV |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | Sharing of knowledge and expertise |
| Collaborator Contribution | Sharing of knowledge and expertise, provision of samples and data from relevant clinical studies |
| Impact | Manuscript in preparation |
| Start Year | 2013 |
| Description | Nottingham - STOP-HCV |
| Organisation | University of Nottingham |
| Department | Division of Microbiology and Infectious Diseases |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge and expertise |
| Collaborator Contribution | Sharing of knowledge and expertise, data management support, provision of study coordination support |
| Impact | Development of STOP-HCV patient registry, establishment of STOP-HCV Cirrhosis Study (UKCRN, observational study) |
| Start Year | 2013 |
| Description | Nottingham - STOP-HCV |
| Organisation | University of Nottingham |
| Department | Nottingham Digestive Diseases Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge and expertise |
| Collaborator Contribution | Sharing of knowledge and expertise, data management support, provision of study coordination support |
| Impact | Development of STOP-HCV patient registry, establishment of STOP-HCV Cirrhosis Study (UKCRN, observational study) |
| Start Year | 2013 |
| Description | OncImmune-STOP-HCV |
| Organisation | Oncimmune |
| Department | Oncimmune |
| Country | United States |
| Sector | Private |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | R&D to develop a diagnostic test to detect hepatocellular cancer |
| Impact | Feasibility testing completed, panel of antigens developed to use for further development and phase 2 testing |
| Start Year | 2013 |
| Description | PHE - HCV NGS pilot |
| Organisation | Public Health England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Provision of samples and data, sharing of knowledge and expertise |
| Collaborator Contribution | Sharing of knowledge and expertise |
| Impact | This collaboration formed part of the STOP-HCV pilot HCV next generation sequencing study - an exercise to formally compare HCV next generation sequencing methods undertaken in different UK centres. Results of the pilot study have been accepted for presentation at the 2016 EASL Liver meeting (April) and a manuscript is under review at the Journal of Clinical Microbiology. |
| Start Year | 2013 |
| Description | QMUL-STOP-HCV |
| Organisation | Queen Mary University of London |
| Department | Blizard Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | Boson study, Merck C-ISLE study |
| Start Year | 2013 |
| Description | Southampton-STOP-HCV |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Sharing of knowledge & expertise |
| Collaborator Contribution | Sharing of knowledge & expertise |
| Impact | none to report to date |
| Start Year | 2013 |
| Description | UCL-HCV NGS pilot |
| Organisation | University College London |
| Department | Department of Infection and Population Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Access to samples and data; expertise and sharing of knowledge |
| Collaborator Contribution | Analysis of samples and data; sharing of knowledge and expertise |
| Impact | This collaboration formed part of the STOP-HCV pilot HCV next generation sequencing study - an exercise to formally compare HCV next generation sequencing methods undertaken in different UK centres. Results of the pilot study have been accepted for presentation at the 2016 EASL Liver meeting (April) and a manuscript is under review at the Journal of Clinical Microbiology. |
| Start Year | 2014 |
| Title | Boson study |
| Description | Large phase 3 study of patients with geno 3a HCV treated with sofosbuvir integrated with STOP-HCV |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | Largest phase-3 hep C study in the UK-major benefits to patients and the economy |
| Title | Early-CDT Liver |
| Description | EarlyCDT-Liver is an autoantibody-based blood test to detect hepatocellular cancer (HCC), in association with imaging, in high risk patients. The test was developed by one of the STOP-HCV consortium's industrial partners (OncImmune) as part of the STOP-HCV project. The test has been launched as a Laboratory Developed Test via Oncimmune's CLIA accredited lab in Kansas, USA and is currently being validated in a clinical setting with collaborators in the US. Funding for the development was provided by OncImmune; patient samples, data and intellectual input were provided by members of the STOP-HCV consortium. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2018 |
| Development Status | Under active development/distribution |
| Impact | Clinical testing is being undertaken with a view to utilising the test as a tool for risk stratification of HCC in patients with cirrhosis, and replacing AFP in Ultrasound+AFP screening strategies. |
| URL | https://oncimmune.com/liver-cancer-blood-test/ |
| Title | STOP-HCV-1 |
| Description | Drugs being used - VIEKIRAX, EXVIERA (Abbvie) and HARVONI (Gilead) - are licensed for use in the UK |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Wide-scale adoption |
| Year Development Stage Completed | 2015 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | Currently recruiting for trial - expected impact will be an improved, stratified approach to short course all-oral drug treatment for HCV infected patients with mild liver disease. |
| URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005004-28 |
| Description | "Vaccines for HCV - where there is a will there is a way" - 9th Canadian Symposium on Hepatitis C February 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The need for and the development of an HCV vaccine was presented |
| Year(s) Of Engagement Activity | 2020 |
| Description | 5th World Congress on Hepatitis and Liver Diseases |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr. Bevin Gangadharan gave a talk at an international conference on hepatitis and liver diseases which sparked questions and discussion from hepatologists around the world. The abtract is below: Background: Liver biopsy is the reference standard for assessing liver fibrosis and no reliable serum biomarkers are available to discriminate between the intermediate stages of fibrosis. We used proteomics to identify novel fibrosis biomarkers in hepatitis C patients with different degrees of liver fibrosis. Methods: Novel liver fibrosis biomarkers were identified by analysing proteins in plasma/serum samples from controls and hepatitis C patients with varying stages of liver fibrosis using a proteomics technique: two dimensional gel electrophoresis (2DE). Identified markers were validated across all Ishak fibrosis stages and compared to the markers used in FibroTest, Enhanced Liver Fibrosis (ELF) test, Hepascore and FIBROSpect by Western blotting. For the most promising biomarkers, an antibody-free assay (parallel reaction monitoring using mass spectrometry) was used which detects tryptic peptides of the biomarkers and their fragments. Results: Forty four candidate biomarkers for hepatic fibrosis were identified of which 20 were novel biomarkers of liver fibrosis. Western blot validation of all candidate markers using plasma samples from patients across all Ishak fibrosis scores showed that the markers which changed with increasing fibrosis most consistently included lipid transfer inhibitor protein, complement C3d, corticosteroid-binding globulin, apolipoprotein J and apolipoprotein L1. These five novel fibrosis markers which are secreted in blood showed a promising consistent change with increasing fibrosis stage when compared to the markers used for the FibroTest, ELF test, Hepascore and FIBROSpect. Conclusion: This study identifies 20 novel fibrosis biomarker candidates. The proteins identified may help to assess hepatic fibrosis and eliminate the need for invasive liver biopsies. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.omicsonline.org/proceedings/discovery-and-quantitation-of-novel-liver-fibrosis-biomarker... |
| Description | A Very Short Introduction to the Immune system (OUP) |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A book for the public on the immune system also accompanied by upcoming talks, blog and e-book. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://global.oup.com/academic/product/the-immune-system-a-very-short-introduction-9780198753902?cc... |
| Description | BSCGT Public Engagement Event - Vaccines & Infectious Disease (hosted stall) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | This all-day event included a series of seminars and a 2hr exhibitor event at which STOP-HCV Consortium hosted a stall. ~100-200 delegates registered for the event, and the target audience was primarily secondary school children and the general public. There was a high level of interest in the stall, from both school children and the general public, and the feedback received will inform plans for future events. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Barnes, E & Hudson, E. STOP-HCV - Stratified Medicine to Optimise Treatment for Hepatitis C Virus Infection. Impact, Volume 2017, Number 6, August 2017, pp. 81-83(3) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | STOP-HCV published an article with Science Impact Ltd showcasing the work of the consortium. The article appeared in the August edition of the magazine (the focus of which is 'Effective and cost-effective solutions') |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.ingentaconnect.com/content/sil/impact/2017/00002017/00000006/art00029 |
| Description | Didcot All Saints Primary School Workshop, 23rd June 2017 'Hand cleanliness, viruses and treatment' - in association with University Hospital Southampton |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Questions and discussions |
| Year(s) Of Engagement Activity | 2017 |
| Description | International Liver Congress, EASL 2017 (Barcelona) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Registry grant presentation" Thursday 14 April 2016 from 12:00 to 13:30. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Interview with Oxford Centre for Personalised Medicine |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview with the Centre for Personalised Medicine (St Anne's College, Oxford) regarding personalised medicine & STOP-HCV. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.well.ox.ac.uk/cpm/prof-ellie-barnes-2 |
| Description | NK cell workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We had a presentation a poster presentation at the NK2017 meeting for the work. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.nk2016.it |
| Description | Oxford Curiosity Carnival, 29th September 2017 (part of 'European Researchers' Night) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Questions, discussions |
| Year(s) Of Engagement Activity | 2017 |
| Description | Public Outreach Session |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Virology outreach talk |
| Year(s) Of Engagement Activity | 2016 |
| Description | Public event (hosted stall) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Stall sparked questions and answers surrounding virology and personalised medicine Positive feedback from attendees at the stall resulted in an invitation to host the stall at another public event (Oxford Open Doors) |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.ndm.ox.ac.uk/cheltenham-science-festival-2014-2 |
| Description | Public event (hosted stall) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Stall sparked interest/further questions surounding virology and personalised medicine Increased awareness for STOP-HCV project - new followers on twitter |
| Year(s) Of Engagement Activity | 2014 |
| Description | Radio packages |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A series of radio packages produced by or involving JKB that were aired on BBC R4 and also BBC World Radio |
| Year(s) Of Engagement Activity | 2016 |
| Description | STOP-HCV Podcast |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Podcast with STOP-HCV researchers describing their work within the consortium. Published on the STOP-HCV website. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.stop-hcv.ox.ac.uk/stop-hcv-podcasts |
| Description | Spotlight on CRN hepatitis C research - interview for website |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Interview for NIHR CRN spotlight on hepatitis C research - published on CRN website |
| Year(s) Of Engagement Activity | 2014 |
| URL | https://www.crn.nihr.ac.uk/hepatology/about-hepatology-research/spotlight-on-hepatitis/researcher/ |
| Description | What is the most effective approach to a HCV vaccine - ILC EASL, Vienna 9th to 13th April 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | European Association of the Study of Liver |
| Year(s) Of Engagement Activity | 2019 |
| Description | World Hepatitis Day, 18th July 2017 (The John Radcliffe Hospital) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Questions and discussion |
| Year(s) Of Engagement Activity | 2017 |